ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO398

Factors Associated with Incident Diabetes in Patients with Glomerular Disease: The CureGN Study

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Mottl, Amy K., University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Mansfield, Sarah, Arbor Research, Ann Arbor, Michigan, United States
  • Palmer, Matthew, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Bomback, Andrew S., Columbia University, New York, New York, United States
  • Nester, Carla M., University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
  • Royal, Virginie, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
  • Barisoni, L., U. Miami, Miller School of Medicine, Miami Beach, Florida, United States
  • Stokes, Michael Barry, Columbia University Medical Center, New York, New York, United States
  • Jennette, J. Charles, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Kretzler, Matthias, U.Michigan, Ann Arbor, Michigan, United States
  • Tuttle, Katherine R., University of Washington School of Medicine, Spokane, Washington, United States
  • Nast, Cynthia C., Cedars-Sinai Medical Center, Los Angeles, California, United States
Background

Glomerular disease is often complicated by incident diabetes which may raise the long-term risk:benefit ratio of immunosuppressive treatment. There is a paucity of information regarding descriptive characteristics of individuals with glomerular disease and incident diabetes.

Methods

We studied 2009 individuals from the CureGN Cohort Study, an observational cohort study of people with IgA Nephropathy/Vasculitis (IgAN/IgAV), Membranous Nephropathy (MN), Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD), followed prospectively starting less than 5 years after kidney biopsy. We compared sociodemographic and clinical characteristics of individuals with versus without incident diabetes diagnosed after kidney biopsy. Statistical significance was calculated using Chi-square or Fisher’s exact test for categorical or Kruskal-Wallis test for continuous variables.

Results

There were 71 individuals with incident diabetes diagnosed a median of 4 (IQR 0-22) months after kidney biopsy. Diabetes was considered medication induced in 44 (62%) and 75% were treated with insulin. Characteristics of individuals with and without incident diabetes are shown in the table. Incident diabetes was more frequent in MN than in other glomerular diseases. Patients with versus without incident diabetes were older, more likely to have a family history of diabetes, and had a greater prevalence of obesity, smoking, hypertension and cardiovascular disease at enrollment. There was no difference in cumulative exposure to steroids between those with versus without incident diabetes.

Conclusion

Incident diabetes was more common in MN than other glomerular diseases, possibly due to older age at presentation of this disease. The absence of a difference in steroid exposure between those with versus without incident diabetes was unexpected and will be the focus of future analyses.

Funding

  • NIDDK Support